Helen X Chen

10PUBLICATIONS
153CO-AUTHORS
Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 11, 2026
ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.

|Nov 19, 2024
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers.

Young Kwang Chae, Lucy Corthell, Sandip Pravin Patel

|Oct 17, 2024
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.

Young Kwang Chae, Megan Othus, Sandip Pravin Patel

|Mar 08, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.

Ryan B Corcoran, Khanh T Do, Jeong E Kim

|Mar 06, 2024
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.

Scott M Schuetze, Karla V Ballman, Rachel Heise

|Aug 02, 2023
The New NCI Precision Medicine Trials.

Lyndsay N Harris, Charles D Blanke, Harry P Erba

Pageof 2

Frequent Collaborators

4 joint publications

Elad Sharon

3 joint publications

Robert J Gray

3 joint publications

Charles D Blanke

3 joint publications

David R Patton